RFK Jr., The FDA, and the Future of Peptides: What Could Change for BPC-157, TB-500, CJC-1295 and More
In this episode we explore the growing conversation around Robert F. Kennedy Jr. and the possibility of several peptides being reconsidered within the FDA regulatory system. Many peptides that were once available through compounding pharmacies were restricted in recent years, leaving physicians and patients without access through traditional medical channels.
We break down the peptides frequently discussed in these regulatory conversations, including BPC-157, TB-500, CJC-1295, Ipamorelin, AOD-9604, GHK-Cu, Thymosin Alpha-1, Epitalon, KPV, LL-37, Kisspeptin-10, Melanotan II, Dihexa, and…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.